摘要
目的:观察吸入沙美特罗/丙酸氟替卡松(舒利迭)治疗儿童重度哮喘的疗效及安全性。方法:72例重度哮喘儿童吸入沙美特罗/丙酸氟替卡松,分别在初诊时及治疗后第2、4、12周评价其日、夜间哮喘症状并计分,记录吸入短效2β受体激动剂的剂数和应用天数,听诊哮鸣音改善情况,比较初诊时和治疗12周后最大呼气流速(PEF)值或第一秒用力呼气量(FEV1)值。结果:经吸入沙美特罗/丙酸氟替卡松(舒利迭)治疗2、4、12周后与初诊基础值比较,患儿日、夜间哮喘症状计分和吸入短效2β受体激动剂(喘乐宁)的剂数均有显著性差异(P<0.01),哮鸣音逐渐减少至消失,第12周时PEF值占预计值的百分比或FEV1值占预计值的百分比和初诊时相比较有显著性差异(P<0.01)。结论:沙美特罗/丙酸氟替卡松(舒利迭)治疗儿童重度哮喘的疗效好,并且安全。
Objective： To evaluate the efficacy ：and side effects of seretide inhalation in treating children with serious asthma. Methods： 72 children with serious asthma were treated with seretide. The asthma symptoms scored in the daytime and the night before the treatment and 2 weeks. 4 weeks, 12 weeks after the treatment were ev＇,duated, and the duration of β2-receptor agonist sneh as albuterol use and use of puffs, as well as ausculated wheezing improvement were reconted. At the same time, all children were measured for peak expiratory, flow （PEF） or forced expiratou volume in 1 second （FEV1） before the treatment and 12 weeks after the treatment. Results： Scores of daytime and night asthma symptoms and albuterol use puffs of 2 weeks, 4 weeks and 12 weeks after the treatment were signifieandy different from the pro-treatment levels （P 〈 0.01）, and the symptoms gradually improved with the treatment time increased, and also the wheezing improved gradually till it disappeared. PEF or FEV1 were signifieantly different between pre-treatment and 12 weeks after the treatment（P 〈 0.01 ）. Conclusion： Seretide inhalation is effective and safe for treating children with serious asthma.
出处
《儿科药学杂志》
CAS
2005年第5期20-22,共3页
Journal of Pediatric Pharmacy
